MAPT and Alzheimer disease: The γ-secretase inhibitor semagacestat, anti-Aβ monoclonal antibodies bapineuzumab and solanezumab, anti-aggregation agent scyllo-inositol (ELND005), RAGE receptor inhibitor (PF-04494700), and tau aggregation inhibitor TRx0237 have displayed no clinical efficacy in phase III trials of mild-to-moderate AD patients [101–106].